Background Treatment innovations have changed prfoundly spondyloarthritis prognosis.
Objectives To assess treatment impact on sleep quality in Axial Spondyloarthritis (AS) patients.
Methods A cross sectional case-control study was conducted between August 2012 and August 2013 in the department of Rheumatology of Charles Nicolle Hospital.
Only patients with Axial Spondyloarthritis according to the 2009 Eular criteria were included. The 100 age- and sex-matched healthy controls were included in this case-control study. Sleep during the month preceding the evaluation was examined by MOS-SS.
Results One hundred patients with AS and 100 control group patients age and sex matched participated in this study. Patients were divided into 71 men and 29 women. Their average age is 41.72 years [16-74]. Seventy four percent of patients were on NSAIDs, 56% were under DMARDs and 12% on TNF alpha blockers.
Controls had fewer sleep problems in all MOSS-SS's fields, compared to AS regardless of the treatment they were receiving, except in the field of snoring, where they were comparable to the patients on biologic DMARDs and significantly lower than NSAID/DMARDS groups. TNF blockers therapy did not show superiority in improving different sleep scores except for one MOSS-SS's domain (Snoring) (table).
Conclusions The impact of treatment was modest. Surprisingly, the TNF blockers therapy did not show superiority in improving different sleep scores except for one MOSS-SS's domain (Snoring).
Disclosure of Interest None declared